A Phase 3 interventional study of DBV712 250 mcg in Peanut Allergy, sponsored by DBV Technologies. Completed at 26 sites in United States. Open to participants aged 2 Years to 5 Years. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by DBV Technologies · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing palforzia in Peanut Hypersensitivity — none open to participants now, 3 under way, 2 of them phase 3. Palforzia · Peanut Hypersensitivity.
Among the 10 studies testing palforzia in Peanut Hypersensitivity, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 6th registered.
166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.
Browse Peanut Hypersensitivity studies →None of the 10 studies testing palforzia in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →
Palforzia: first FDA approval 2020 (Palforzia). What it is approved for, and how studies give it, is on its page →
Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 2 Years to 5 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2018.
This study's enrollment of 304 is above the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.
Median enrollment 105 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
DBV Technologies is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
13 studies in Peanut Hypersensitivity by DBV Technologies: none open now, 2 under way, 2 of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 13 studies in Peanut Hypersensitivity by DBV Technologies, this one is the 6th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2018, is one of 7 in phase 3, and was the 9th registered.
DBV Technologies’s Peanut Hypersensitivity studies by the year they started, since 2010.
1 of the studies testing palforzia in Peanut Hypersensitivity that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing palforzia in Peanut Hypersensitivity, from their registry updates:
Among DBV Technologies’s 13 in Peanut Hypersensitivity:
This tab as a report to print or save as PDF → With an account.
Open-label, follow-up study for subjects who completed the EPITOPE study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
DBV712 250 mcg, once daily
Biological: DBV712 250 mcg
DBV712 250 mcg, once daily
Percentage of Participants Who Were Treatment Responders at Months 12, 24, 36 and 48
A participant was defined as treatment responder if: * The V712-304 (EPITOPE) baseline ED was \>10 mg peanut protein and the ED was ≥1000 mg peanut protein at the post-baseline DBPCFCs or; * The V712-304 (EPITOPE) baseline ED was ≤10 mg and the ED is ≥300 mg peanut protein at the post-baseline DBPCFCs. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
Time frame: Months 12, 24, 36 and 48
Percentage of Participants Reaching an ED ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48
ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
Time frame: Months 12, 24, 36 and 48
Percentage of Participants Who Tolerated ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48
Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
Time frame: Months 12, 24, 36 and 48
Percentage of Participants Who Tolerated ≥ 2000 mg Peanut Protein at Months 12, 24, 36 and 48
Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
Time frame: Months 12, 24, 36 and 48
Tolerated Doses of Peanut Protein at Baseline and Months 12, 24, 36 and 48
Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
Time frame: Baseline and Months 12, 24, 36 and 48
EDs of Peanut Protein at Baseline and Months 12, 24, 36 and 48
ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
Time frame: Baseline and Months 12, 24, 36 and 48
Cumulative Reactive Doses (CRD) of Peanut Protein at Baseline and Months 12, 24, 36 and 48
CDR was defined, at every DBPCFC, as the sum of all the doses consumed (in mg) of food protein, including the eliciting dose. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
Time frame: Baseline and Months 12, 24, 36 and 48
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs), Serious AEs (SAEs), and AEs of Special Interest (AESI)
TEAEs: any AE occurring at first EPOPEX VP patch application or pre-existing but worsening in either severity or relationship to the IMP following initial exposure to VP patch in EPOPEX trial. Clinically significant changes in vital signs, physical exams, or labs after first IMP were considered TEAEs. SAE: any event resulting in death, life-threatening condition, hospitalization or its prolongation, significant or persistent disability, congenital anomaly or birth defect, or any important medical event that may not be immediately life-threatening but could jeopardize the participant or require intervention to prevent such outcomes. AESI: local (any patch-site reaction that could disrupt the skin barrier) and systemic (immediate systemic allergic reaction after exposure to a known/suspected allergen, including anaphylaxis or hypersensitivity requiring epinephrine, outside DBPCFCs). AEs from accidental peanut intake and SAEs related to DBPCFC were excluded.
Time frame: During 36 months of active treatment
Number of Participants Who Experienced SAEs During DBPCFC After Peanut Formula at Months 12, 24, 36 and 48
A SAE was defined as any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; was a congenital anomaly or birth defect; was an important medical event that may not be immediately life-threatening or result in death or hospitalization but that may jeopardize the participant or require intervention to prevent one of the above outcomes. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
Time frame: Months 12, 24, 36 and 48
Percentage of Participants Reaching an Eliciting Dose (ED) ≥ 1000 mg Peanut Protein at Months 12, 24, 36 and 48
ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and at every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12)
Time frame: 12, 24, 36, 48 months
| Milestone | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Started | 205 | 99 |
| Completed | 144 | 56 |
| Not completed | 61 | 43 |
| Withdrew: Withdrawal by subject | 47 | 33 |
| Withdrew: Physician decision | 4 | 1 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Miscellaneous | 5 | 2 |
| Withdrew: Lost to follow-up | 3 | 2 |
| Withdrew: Protocol violation | 0 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 1 |
A participant was defined as treatment responder if: * The V712-304 (EPITOPE) baseline ED was \>10 mg peanut protein and the ED was ≥1000 mg peanut protein at the post-baseline DBPCFCs or; * The V712-304 (EPITOPE) baseline ED was ≤10 mg and the ED is ≥300 mg peanut protein at the post-baseline DBPCFCs. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
| Participants | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Month 12 | 154 | 38 |
| Month 24 | 159 | 55 |
| Month 36 | 140 | 48 |
| Month 48 | — | 39 |
ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
| Participants | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Month 12 | 96 | 13 |
| Month 24 | 111 | 29 |
| Month 36 | 109 | 27 |
| Month 48 | — | 24 |
Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
| Participants | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Month 12 | 107 | 18 |
| Month 24 | 135 | 36 |
| Month 36 | 120 | 33 |
| Month 48 | — | 27 |
Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
| Participants | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Month 12 | 68 | 7 |
| Month 24 | 96 | 23 |
| Month 36 | 103 | 23 |
| Month 48 | — | 22 |
Tolerated Dose (TD) was defined, at every DBPCFC, as the maximum single peanut protein dose that was associated with no or mild (not dose limiting) symptoms, based upon standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
| mg | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Baseline | 51.4 ± 42.15 | 61.7 ± 41.39 |
| Month 12 | 949.9 ± 816.95 | 343.2 ± 549.30 |
| Month 24 | 1289.2 ± 811.85 | 841.9 ± 811.59 |
| Month 36 | 1396.6 ± 803.78 | 898.6 ± 866.91 |
| Month 48 | — | 937.9 ± 879.39 |
ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
| mg | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Baseline | 152.9 ± 123.9 | 176.9 ± 121.27 |
| Month 12 | 1264.5 ± 766.39 | 592.1 ± 657.18 |
| Month 24 | 1110.7 ± 752.76 | 419.0 ± 648.12 |
| Month 36 | 1424.0 ± 684.35 | 989.3 ± 797.85 |
| Month 48 | — | 1230.8 ± 779.69 |
CDR was defined, at every DBPCFC, as the sum of all the doses consumed (in mg) of food protein, including the eliciting dose. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
| mg | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Baseline | 224.0 ± 182.63 | 260.0 ± 176.23 |
| Month 12 | 2078.7 ± 1352.78 | 918.9 ± 1094.03 |
| Month 24 | 2512.1 ± 1255.18 | 1813.2 ± 1355.79 |
| Month 36 | 2678.6 ± 1233.02 | 1892.4 ± 1399.94 |
| Month 48 | — | 2033.3 ± 1381.11 |
TEAEs: any AE occurring at first EPOPEX VP patch application or pre-existing but worsening in either severity or relationship to the IMP following initial exposure to VP patch in EPOPEX trial. Clinically significant changes in vital signs, physical exams, or labs after first IMP were considered TEAEs. SAE: any event resulting in death, life-threatening condition, hospitalization or its prolongation, significant or persistent disability, congenital anomaly or birth defect, or any important medical event that may not be immediately life-threatening but could jeopardize the participant or require intervention to prevent such outcomes. AESI: local (any patch-site reaction that could disrupt the skin barrier) and systemic (immediate systemic allergic reaction after exposure to a known/suspected allergen, including anaphylaxis or hypersensitivity requiring epinephrine, outside DBPCFCs). AEs from accidental peanut intake and SAEs related to DBPCFC were excluded.
| Participants | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| TEAEs (total) | 205 | 99 |
| TEAEs related to IP | 205 | 99 |
| SAEs (total) | 26 | 11 |
| SAEs related to IP | 1 | 1 |
| Local AESI | 60 | 21 |
| Systemic AESI | 40 | 12 |
A SAE was defined as any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability or incapacity; was a congenital anomaly or birth defect; was an important medical event that may not be immediately life-threatening or result in death or hospitalization but that may jeopardize the participant or require intervention to prevent one of the above outcomes. DBPCFC occurred at baseline and every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12).
| Participants | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Month 12 | 3 | 5 |
| Month 24 | 1 | 2 |
| Month 36 | 0 | 1 |
| Month 48 | — | 0 |
ED was defined, at every DBPCFC, as the peanut protein dose that triggered any dose-limiting symptom, defined by standardized criteria. DBPCFC occurred at baseline and at every 12 months, with the first post-baseline one being performed at the end of the EPITOPE trial (corresponding to Month 12)
| Participants | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Month 12 | 147 | 34 |
| Month 24 | 153 | 51 |
| Month 36 | 137 | 43 |
| Month 48 | — | 39 |
Collected over Up to 3 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DBV712 250mcg+DBV712 250mcg | 0/205 (0%) | 26/205 (12.7%) | 205/205 (100%) |
| Placebo+DBV712 250mcg | 0/99 (0%) | 11/99 (11.1%) | 99/99 (100%) |
| Event | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| AsthmaRespiratory, thoracic and mediastinal disorders | 1/205 | 4/99 |
| Anaphylactic ReactionImmune system disorders | 5/205 | 3/99 |
| WheezingRespiratory, thoracic and mediastinal disorders | 6/205 | 0/99 |
| Gastroenteritis ViralInfections and infestations | 1/205 | 1/99 |
| Viral InfectionInfections and infestations | 1/205 | 1/99 |
| OsteomyelitisInfections and infestations | 0/205 | 1/99 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/205 | 1/99 |
| Bronchial hyperreactivityRespiratory, thoracic and mediastinal disorders | 2/205 | 0/99 |
| Medication ErrorInjury, poisoning and procedural complications | 2/205 | 0/99 |
| Food AllergyImmune system disorders | 1/205 | 0/99 |
| Event | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg |
|---|---|---|
| Application Site ErythemaGeneral disorders | 202/205 | 97/99 |
| Application Site PruritisGeneral disorders | 196/205 | 93/99 |
| Application Site SwellingGeneral disorders | 152/205 | 65/99 |
| PyrexiaGeneral disorders | 92/205 | 59/99 |
| Upper Resperatory tract infectionInfections and infestations | 116/205 | 50/99 |
| UrticariaSkin and subcutaneous tissue disorders | 98/205 | 53/99 |
| EczemaSkin and subcutaneous tissue disorders | 72/205 | 42/99 |
| VomitingGastrointestinal disorders | 73/205 | 33/99 |
| Corona Virus InfectionInfections and infestations | 43/205 | 34/99 |
| Viral InfectionInfections and infestations | 63/205 | 32/99 |
| Age, Categorical(Participants) | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg | Total |
|---|---|---|---|
| <=18 years | 205 | 99 | 304 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg | Total |
|---|---|---|---|
| Mean | 2.6 ± 0.86 | 2.5 ± 0.86 | 2.5 ± 0.86 |
| Sex: Female, Male(Participants) | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg | Total |
|---|---|---|---|
| Female | 68 | 28 | 96 |
| Male | 137 | 71 | 208 |
| Race/Ethnicity, Customized(Participants) | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg | Total |
|---|---|---|---|
| White | 140 | 59 | 199 |
| Asian | 33 | 19 | 52 |
| Black or African American | 0 | 0 | 0 |
| Other | 29 | 15 | 44 |
| Not collected | 3 | 6 | 9 |
| Region of Enrollment(participants) | DBV712 250mcg+DBV712 250mcg | Placebo+DBV712 250mcg | Total |
|---|---|---|---|
| United States | 123 | 61 | 184 |
| United Kingdom | 21 | 9 | 30 |
| Australia | 35 | 14 | 49 |
| Canada | 9 | 4 | 13 |
| France | 0 | 2 | 2 |
| Germany | 3 | 3 | 6 |
| Ireland | 11 | 3 | 14 |
| Netherlands | 3 | 3 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in May 2025, 77 months.
Results were first posted in Oct 2026, 1 year 5 months after primary completion.
Of 15 phase 3 interventional studies under Peanut Hypersensitivity, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 42. This study's 77 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palforzia
DBV Technologies